Group 1 - The core point of the article is that 基石药业 (Basehill Pharmaceuticals) announced a new share placement to raise approximately HKD 470 million through the issuance of 100 million new shares [1] - The placement price is set at HKD 4.72 per share, which represents an 8.9% discount to the previous closing price of HKD 5.18 and a 3.0% discount to the average closing price over the last five trading days [1] - After the placement, the new shares will account for approximately 7.3% of the existing issued share capital and about 6.8% of the enlarged share capital [1] Group 2 - The funds raised will primarily be used for further research and development related to the company's "Pipeline 2.0" assets, with approximately HKD 420 million allocated for this purpose and HKD 50 million for general corporate purposes [1] - The issuance is conducted under a general mandate granted by the shareholders' meeting and is expected to be completed by July 16, 2025 [1] - Morgan Stanley is acting as the sole global coordinator, sole placing agent, and sole bookrunner for this financing [1]
基石药业（2616）公告：通过一般授权配售新股募资约4.7亿港元 抗肿瘤药物研发
Xin Lang Cai Jing·2025-07-11 07:27